SCHEMBL2243540

SCHEMBL2243540

CC1(OC(=O)N2CC(OCC3CCN(c4ncc5c(n4)CCN(S(C)(=O)=O)C5)CC3)C2)CC1

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
HCRTR2 O43614 1/20 0.39
GPR119 Q8TDV5 8/20 0.39
ENPP2 Q13822 1/20 0.35
HSP90AB1 P08238 5/20 0.33
HSP90AA1 P07900 2/20 0.33
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12356460 0.94 GPR119 (0.42) MAPTHCRTR2GPR119ENPP2CYP2C9
SCHEMBL12356461 0.89 MAPT (0.53) MAPTGPR119
SCHEMBL2246273 0.85 GPR119 (0.39) MAPTHCRTR2GPR119ENPP2HSP90AB1
SCHEMBL12356487 0.85 GPR119 (0.39) MAPTHCRTR2GPR119ENPP2HSP90AB1
SCHEMBL12367370 0.85 GPR119 (0.39) MAPTHCRTR2GPR119ENPP2HSP90AB1
SCHEMBL2247534 0.83 GPR119 (0.38) MAPTHCRTR2GPR119ENPP2HSP90AB1
SCHEMBL3400919 0.83 GPR119 (0.38) MAPTHCRTR2GPR119ENPP2HSP90AB1
SCHEMBL2245448 0.80 GPR119 (0.40) MAPTGPR119
SCHEMBL2245181 0.80 GPR119 (0.40) MAPTGPR119
SCHEMBL12356463 0.78 GPR119 (0.41) MAPTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190263-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US claimed
EP-2252613-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM, LLC (BM) 2010-11-24 EP claimed
WO-2009105717-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-08-27 WO claimed
US-20110190263-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190263-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
US-20110190263-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-08-04 US disclosed
EP-2252613-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM, LLC (BM) 2010-11-24 EP disclosed
WO-2009105717-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-08-27 WO disclosed
WO-2009105717-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190263-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 MAPT 4009/4885HCRTR2 113/4885GPR119 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.